Company intelligence / Profile preview

3D BioOptima

Suzhou, Jiangsu, Chinaen.3dbiooptima.com ↗

Ownership: Private
Employees: ~80
Development stage: Commercial

Overview

3D BioOptima is an established Chinese contract research organization specializing in preclinical drug development services. It has completed over 400 IND-enabling ADME package studies supporting global regulatory submissions. Its work has enabled more than 300 compounds to enter clinical trials with NMPA approval and over 200 with US FDA or Australian TGA approval.

Modalities: Small moleculePeptideAntibody-drug conjugateLarge molecule
Industry: Contract Research Organization

Beyond the preview

Go deeper on 3D BioOptima.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3D BioOptima.

Explore the full profile